VulnerabilityModified
CVE-2015-3965
Hospira Symbiq Infusion System 3.13 and earlier allows remote authenticated users to trigger "unanticipated operations" by leveraging "elevated privileges" for an unspecified call to an incorrectly exposed function.
HIGH 8.8EPSS 2.88%
Does this matter?
High impact if exploited, but EPSS currently rates exploitation as unlikely (2.88%). Schedule it in the normal patch cycle and watch for a rise in EPSS or a public exploit.
Description
Hospira Symbiq Infusion System 3.13 and earlier allows remote authenticated users to trigger "unanticipated operations" by leveraging "elevated privileges" for an unspecified call to an incorrectly exposed function.
- CVSS 3.0
- 8.8 HIGHCVSS:3.0/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H
- EPSS
- 2.88% probability · 86th percentile
- CISA KEV
- Not listed
- Weakness
- CWE-264
- Affected
- pfizer/symbiq infusion system firmware
- Source
- ics-cert@hq.dhs.gov
References
- https://ics-cert.us-cert.gov/advisories/ICSA-15-174-01Third Party Advisory, US Government Resource
- https://ics-cert.us-cert.gov/advisories/ICSA-15-174-01Third Party Advisory, US Government Resource
Source: NVD record, EPSS from FIRST.org, KEV from CISA. Refreshed daily.